Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Novartis: Gilenya Effective Against 4 Measures Of Disease Activity In MS

Swiss drugmaker Novartis AG (NVS: Quote) Monday said that two new analyses from the Phase III Transforms study demonstrated how its Gilenya (fingolimod) was effective against all four key measures of disease activity in multiple sclerosis - brain volume loss, lesion activity, relapse rates and disability progression.

Improvements were seen in patients who switched from standard interferon treatment to Gilenya within 12 months of the switch and up to the end of the 4.5 year extension study.

MS is a chronic neuroinflammatory and neurodegenerative illness where disease activity leads to accumulation of disability and loss of brain tissue.

The new analysis evaluated the association between measures of disease activity in the first year of therapy and long-term clinical outcomes. Gilenya increased the proportion of patients who were disease-free by almost 50 percent when switched from interferon to Gilenya in year-1 to year-2.

Patients who had disease-activity at the end of the first year were significantly less likely to remain clinically disease free during the following 3.5 years of the extension study.

A separate post-hoc analysis showed that patients who had disease-activity in the year prior to entering the study, despite prior treatment with a disease-modifying treatment, experienced sustained benefit on Gilenya with a lower annualized relapse rate compared to those who were given interferon for the first year.

The analyses were presented at the 23rd meeting of the European Neurological Society or ENS in Barcelona.

Dr. Timothy Wright, Global Head Development, Novartis Pharmaceuticals, said, "Data have consistently shown that treatment with Gilenya leads to more patients staying disease free, compared to standard interferon treatment."

Register
To receive FREE breaking news email alerts for Novartis AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.